ARTICLE | Clinical News
LOR-2040 regulatory update
June 30, 2008 7:00 AM UTC
EMEA's Committee for Orphan Medical Products (COMP) granted Orphan Drug designation for Lorus' LOR-2040 to treat acute myeloid leukemia (AML). The antisense compound that binds to the R2 component of ...